Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
Rasburicase has been defined as a potent urolytic agent for management of malignancy-associated hyperuricemia. We reviewed the data of 26 children with malignancy at risk for TLS who received rasburicase for treatment or prophylaxis of acute hyperuricemia, producing a significant decrease in uric acid level in all the patients. Tolerance of treatment was excellent. Rasburicase is a safe, highly and rapidly effective agent in the treatment and prevention of malignancies-associated acute hyperuricemia.
Pession
Andrea
A
Barbieri
Eveline
E
Santoro
Nicola
N
Paolucci
Paolo
P
Porta
Fulvio
F
Locatelli
Franco
F
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000517:prevention & control*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015275:Tumor Lysis Syndrome / Q000188:drug therapy / Q000209:etiology; D014503:Urate Oxidase / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase